BTK inhibitors

MA strategy deal block push come together form
Biotech

Processa acquires Vidya for potential rival to Rhapsido

The deal secures Processa an oral BTK inhibitor that the companies say improves on the efficacy and safety of earlier BTKi programs.
James Waldron Jul 29, 2026 10:10am
Roche

Roche unpacks death imbalance in multiple sclerosis ph. 3 trials

Apr 21, 2026 7:15pm
Completing steps towards success checkmark on cubes symbolizing progress

Roche reports pivotal MS win, but deaths add to safety questions

Mar 2, 2026 6:00am
Completing steps towards success checkmark on cubes symbolizing progress

Roche unveils data behind BTK inhibitor's phase 3 MS win

Feb 9, 2026 7:00am
An envelope with rejected mark Vector illustration

FDA shares CRL for Sanofi MS drug mere weeks after rebuff

Jan 6, 2026 4:30am
Job cuts employee layoffs firings or downsizing Scissors dividing individuals positioned on colorful blocks

Nurix trims staff as trial for lead BTK degrader kicks off

Nov 21, 2025 5:05am